AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05721066 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory analysis
Description: Blood count and standard coagulation tests (INR, aPTT, fibrinogen, D-dimers, antithrombin)
Study NCT05721066 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Questionnaire from ISS (Istituto Superiore Sanità, the National Health Institute) about the health conditions before the acute COVID-19 infection, the disease (and the hospitalization) details and the eventual health disturbances experienced after the recovery from COVID-19 infection.
Study NCT06360913 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High resolution mass spectrometry
Description: Metabolomics study
Study NCT05921955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow high-flow nasal cannula system
Description: Using the Optiflow high-flow nasal cannula system to supply oxygen for maternal.
Study NCT06545357 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: To conduct this intervention, we used disposable acupuncture needles with the size of 0.30 x 25 mm to acupuncture at biceps brachii muscle, supraspinatus muscle and deltoid muscles or acupoints on The Yang Ming Channel for 20 minutes, frequency ≤ 20 Hz, intensity from 2- 10mA
Study NCT06545357 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: To conduct this intervention, we used disposable acupuncture needles with the size of 0.30 x 25 mm to acupuncture at biceps brachii muscle, supraspinatus muscle and deltoid muscles or acupoints on The Yang Ming Channel for 20 minutes, frequency ≤ 20 Hz, intensity from 2- 10mA
Study NCT05176912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Reformer Pilates exercises will given for 8 weeks, 3 days in a week
Study NCT06124131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive for colorectal cancer screening
Description: $50 incentive paid to participant for completion of colorectal cancer screening within 2 months of enrollment
Study NCT06124131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive for flu shot
Description: $50 incentive paid to participant for completion of flu shot within 2 months of enrollment
Study NCT06124131 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial incentive for flu shot
Description: $50 incentive paid to participant for completion of flu shot within 2 months of enrollment
Study NCT06124131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive for COVID-19 shot
Description: $50 incentive paid to participant for completion of COVID-19 shot within 2 months of enrollment
Study NCT06124131 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial incentive for COVID-19 shot
Description: $50 incentive paid to participant for completion of COVID-19 shot within 2 months of enrollment
Study NCT06540469 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iodine Supplementation in Whole Course of Treatment with ATDs
Description: Moderate iodine supplementation (150μg iodine per day, equivalently 7-9g iodized salt per day) will be taken from ATDs treatment starting until 1 year after ATDs withdrawal.
Study NCT06540469 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iodine Supplementation During Maintenance Treatment with ATDs
Description: Iodine restriction (non-iodized salt and low iodine diet) will be demanded at the early course of ATDs treatment, and moderate iodine supplementation (150μg iodine per day, equivalently 7-9g iodized salt per day) will be taken when the ATDs dose is titrated down to a maintenance level until 1 year after ATDs withdrawal.
Study NCT06540469 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Iodine Restriction in Whole Course of Treatment with ATDs
Description: Iodine restriction (non-iodized salt and low iodine diet) will be demanded from ATDs treatment starting until 1 year after ATDs withdrawal.
Study NCT06540469 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: anti-Thyroid Drugs
Description: Individualized methimazole (MMI)
Study NCT06540469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-Thyroid Drugs
Description: Individualized methimazole (MMI)
Study NCT05536531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Description: Electrical stimulator (Electrostimulator TRAINFES 6 ADVANCED, Biomedical devices Spa, Santiago, Chile.) to administer NMES
Study NCT05451446 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: proprietary water
Description: They are randomized to consume a proprietary water product for five-free living days and to drink on the heat stress chamber day.
Study NCT05451446 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: They are randomized to consume a carbohydrate drink for five-free living days and to drink on the heat stress chamber day.
Study NCT05451446 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: They are randomized to consume water for five-free living days and to drink on the heat stress chamber day.
Study NCT06540404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulse traction
Description: The subjects underwent impulse traction of the knee joint in the second degree according to the Kaltenborn concept.
Study NCT06540404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous traction
Description: The subjects underwent continuous traction of the knee joint in the third degree according to the Kaltenborn concept.
Study NCT06540404 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham therapy
Description: The therapist did not use traction force, the knee joint was kept in a flexed position of 40 degrees.
Study NCT04874545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Total intravenous inhalational anesthesia
Study NCT04874545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Total intravenous inhalational anesthesia
Study NCT06548191 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Time-restricted eating
Description: Fasting (abstinence from calorie-containing food or drink) during 14 h at night, with no caloric consumption after 8 pm to align with circadian rhythms
Study NCT05797077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colorectal resection surgery.
Description: Colorectal cancer radical resection combined with liver metastasis resection or ablation.
Study NCT05797077 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Colorectal resection surgery.
Description: Colorectal cancer radical resection combined with liver metastasis resection or ablation.
Study NCT05797077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX chemotherapy regimen
Description: Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
Study NCT05797077 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: FOLFOX chemotherapy regimen
Description: Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
Study NCT05797077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Maintenance therapy is recommended to be continued with low-toxicity drugs such as 5-FU/LV or capecitabine, and may be combined with targeted therapy. Treatment should be discontinued once ctDNA testing is negative.
Study NCT04399083 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine will be administered to each participant following an individualized optimal dosing schedule created by the 2B-Alert app. Individualized caffeine dosing schedules will be created by the 2BAlert app on the smartphone the participant uses to do Smart-PVT tests. Study staff will run the optimization at 1900 on Day 15. The algorithm will recommend caffeine dosing to optimize performance during the Peak Alertness window (e.g. from 0300-0900 on Day 16, 44-50 hours of continuous sleep loss). Doses could be recommended at any hour from 2000 on Day 15 to 0800 on Day 16. HOWEVER, the algorithm will not exceed 800 mg of caffeine across the entire study AND it will not dose more than 300 mg of caffeine at a time. Gum will be chewed for a total of 10 minutes by each participant and then discarded.~As there will be no placebo in this protocol, randomization and blinding procedures are not necessary. IT IS IMPORTANT TO NOTE THAT SOME PARTICIPANTS MAY NOT RECEIVE CAFFEINE AT ALL.
Study NCT04345666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate
Description: The intervention of this study is to treat patients to either 1) testosterone cypionate or 2) placebo (sterile saline) to determine if there is a difference in recovery times after arthroscopic rotator cuff repair
Study NCT04345666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The intervention of this study is to treat patients to either 1) testosterone cypionate or 2) placebo (sterile saline) to determine if there is a difference in recovery times after arthroscopic rotator cuff repair
Study NCT04772677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BEAM Mental Health and Parenting Program
Description: The BEAM program is a novel mobile app-based therapeutic intervention that incorporates key parenting concepts and Unified Protocol (UP) therapy modules with clinician-facilitated peer social support and connection. The primary aim of the program is to improve symptoms of depression and promote a positive parent-child relationship. There are three main components of the program: 1) the UP content, which will target maternal mental health symptomology, 2) the parenting skills training content, which is designed to correspond to the UP modules and promote maternal responsivity to children's emotions, and 3) a closed online community forum to encourage social support and connection between participants of the program.
Study NCT04904224 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Panintestinal video capsule endoscopy
Description: Performing a video capsule endoscopy using the Pill Cam Crohn's capsule from Medtronic
Study NCT04904224 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Performing a standard colonoscopy using the colonoscope available in the study center
Study NCT06218472 — intervention group
Intervention type: OTHER
Intervention: Day Hospital Treatment
Description: Scheduling of 12 half-day sessions per week, alternating between sessions with only the patients or involving the entire family. Close medical monitoring and multidisciplinary interventions during sessions (pediatrician, psychiatrist, dietitian, recovered former patients...).
Study NCT06218472 — intervention group
Intervention type: OTHER
Intervention: Multidisciplinary follow-up as usual within the service
Description: Multidisciplinary follow-up as usual within the service
Study NCT06218472 — intervention group
Intervention type: OTHER
Intervention: Conduct semi-structured qualitative interviews
Description: Conduct semi-structured qualitative interviews
Study NCT05300945 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: HIPEC after gastrectomy with D2 local lymph node dissection.
Study NCT06364995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volleyball
Description: Volleyball Specialised Physical Education Intervention is a step-by-step approach to teaching the intervention. Each lesson was conducted as a Warm-up (10 minutes), Basic contents of the PE lesson (25 minutes), and Cool-down (5 minutes). From the learning of basic skills in the first session to the final Combination Practice underhand service, receive, service, pass, spiking, and block, from the simple to the difficult, the intensity of the training is from weak to strong, Allowing participants to build upon a solid foundation toward mastering intricate volleyball maneuvers. Intensity modulation is key to this intervention; training intensity evolves from moderate to vigorous, aligning with the increasing complexity of skills and the physical demand required to execute them proficiently. The curriculum is thoughtfully designed to transition from basic skill execution to complex gameplay, with each lesson introducing new skills or refining existing ones.
Study NCT06364995 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Education
Description: Participants participating in the control group will attend traditional physical education classes following the established physical education syllabus. Participants in the control group will attend four 40-minute classes per week over ten weeks. Each session will consist of a warm-up (10 minutes), the basics of PE (25 minutes), and a cool-down (5 minutes). The duration and intensity of the experimental and control groups were the same, which allowed for a better comparison.
Study NCT06314464 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Praxis
Description: Praxis' gaze stabilization exercises are delivered via the tablet-based VestAid software that uses the tablet camera to automatically assess compliance in the conduct of vestibulo-ocular reflex exercises. The smooth pursuit, saccade, agility, and dual tasking exercises are delivered in the form of military-themed mixed reality games using the HTC Vive Focus 3 headset.
Study NCT06314464 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised cardiovascular exercise
Description: The supervised cardiovascular exercise does not incorporate gaze stabilization exercises (vestibulo-ocular reflex exercises) or smooth pursuit, saccade, agility, and dual tasking exercises.
Study NCT05635890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cawthorne Cooksey exercise protocol
Description: Cawthorne Cooksey exercise protocol
Study NCT05635890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional vestibular rehabilitation
Description: conventional vestibular rehabilitation
Study NCT05635890 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional vestibular rehabilitation
Description: conventional vestibular rehabilitation
Study NCT05286060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-188E, GX-I7, Pembrolizumab
Description: Drug 1: GX-188E GX-188E, 2mg (1.0mg/0.5ml/vial), Intramuscular administration using electroporator Other Name: Tirvalimogene teraplasmid Drug 2: GX-I7 GX-I7 1200㎍/kg, intramuscular administration Other Name: NT-I7, rhIL-7-hyFc, efineptakin alfa Drug 3: Pembrolizumab pembrolizumab 200mg (100mg/4mL/vial), Intravenous administration Other Name: Keytruda®
Study NCT05286060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-188E, Pembrolizumab
Description: Drug 1: GX-188E GX-188E, 2mg (1.0mg/0.5ml/vial), Intramuscular administration using electroporator Other Name: Tirvalimogene teraplasmid Drug 2: Pembrolizumab pembrolizumab 200mg (100mg/4mL/vial), Intravenous administration Other Name: Keytruda®
Study NCT05286060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-188E, GX-I7, Pembrolizumab
Description: Drug 1: GX-188E GX-188E, 2mg (1.0mg/0.5ml/vial), Intramuscular administration using electroporator Other Name: Tirvalimogene teraplasmid Drug 2: GX-I7 GX-I7 360㎍/kg, intramuscular administration Other Name: NT-I7, rhIL-7-hyFc, efineptakin alfa Drug 3: Pembrolizumab pembrolizumab 200mg (100mg/4mL/vial), Intravenous administration Other Name: Keytruda®
Study NCT05286060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-188E, GX-I7
Description: Drug 1: GX-188E GX-188E, 2mg (1.0mg/0.5ml/vial), Intramuscular administration using electroporator Other Name: Tirvalimogene teraplasmid Drug 2: GX-I7 GX-I7 360㎍/kg, intramuscular administration Other Name: NT-I7, rhIL-7-hyFc, efineptakin alfa
Study NCT05150548 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Not applicable, non-interventional study
Study NCT05818865 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CLG
Description: The development of an innovative device (CLG) consisting of an aqueous gel based on hyaluronic acid and commercially available (Belotero) able to be loaded and to release chemokine CXCL12 recreating a kind of fake niche able to attract immune cells- and CTCs-CXCR4+. The added value is the ability to attract and trap cells capable of leaking out and potentially with a higher metastatic capacity.
Study NCT05032950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam administered as a single dose on Day 1
Study NCT05032950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332/ritonavir + Midazolam
Description: PF-07321332/ritonavir:~Administered orally every 12 hours for a total of 9 doses on Days 1-5~Midazolam:~Administered orally as a single dose on Day 5
Study NCT05032950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir + Midazolam
Description: Ritonavir:~Administered orally every 12 hours for a total of 9 doses on Day1-5.~Midazolam:~Administered orally as a single dose on Day 5
Study NCT05764967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Dye Taping
Description: The augmented low-Dye technique, involves applying a device consisting of a spur and mini-stirrups to the foot and then adding reverse sixes and calcaneal slings to an anchor on the distal one-third of the leg. A rigid 38-mm sports tape with zinc oxide adhesive is used for all of the taping procedures.
Study NCT05764967 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Temporary Felt Insoles
Description: A temporary orthosis is fabricated from 7-mm orthopedic felt.The subject stands on his or her template while the TTR pointer is attached to the medial tibial plateau of the leg using a Velcro strap. An outline of the position of the device on the tibial plateau is drawn onto the skin with an indelible ink pen to allow for accurate relocation between all trials. TTR is measured in relaxed calcaneal stance while the subject wearing shoes. Measurements are recorded onto a data-collection sheet. Each measurement performes twice. The subject are given orthosis inserted into the shoe. All shoes are visually assessed to ensure that they will not induce pronation or internal rotation.
Study NCT06542146 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: The Mediterranean diet is consisting of fruits, vegetables , legumes, whole grains, nuts, and olive oil as the main source ofdietary fat
Study NCT06542146 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Usual diet
Description: Usual diet including routine diet we already eat
Study NCT04785365 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biological: ATL001
Description: No investigational product will be administered
Study NCT06037668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BVR-100
Description: Experimental self-guided VR intervention for the treatment of SAD
Study NCT06037668 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BES-100
Description: Active at-home VR intervention comparator
Study NCT06538285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 0.50 mg/kg IM will be administered during the first dosing visit, and either 0.50 mg/kg IM or 0.75 mg/kg IM will be administered at the two subsequent dosing visits, depending on the participant's toleration of prior ketamine dose(s). All ketamine dosing visits will be facilitated by a licensed study therapist and clinician (i.e., NP or MD).
Study NCT06591377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90 MG
Description: The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin
Study NCT06591377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol 100 MG
Description: The cilostazol arm will receive (a 200 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
Study NCT06591377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 75mg
Description: The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin
Study NCT06591377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 75mg
Description: The cilostazol arm will receive (a 200 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
Study NCT06538285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Psychotherapy will consist of three 1-hour preparatory talk therapy sessions over the 14 days preceding the first ketamine dosing visit, a 1-hour integration talk therapy session within 1-3 days following each ketamine dosing visit, and a final 1-hour integration talk therapy session about 1 week following the last ketamine visit. All talk therapy visits will be conducted by a licensed study therapist.
Study NCT06540079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solia CSP S lead
Description: The Solia CSP S pacing lead will be implanted in the LBBA for patients who meet all inclusion/exclusion criteria and give written informed consent.